Triple-Drug attack on brain metastases: new hope for melanoma patients?
NCT ID NCT06712927
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 35 times
Summary
This phase 2 trial is testing a combination of three immune-boosting drugs (relatlimab, nivolumab, and ipilimumab) in 60 people with melanoma that has spread to the brain. The study includes both patients with and without symptoms from their brain tumors. The main goal is to see if the treatment can shrink or stabilize brain tumors for at least 6 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Stanford University
RECRUITINGPalo Alto, California, 94304, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Relatlimab, nivolumab, and ipilimumab (immune-boosting drugs given by IV)
What this could lead to
If it works, this could offer a new treatment option for people with melanoma that has spread to the brain, potentially shrinking tumors and controlling the disease longer.
What could go wrong
This is an early-phase trial with only 60 participants, so results may not apply to everyone. The drug combination can cause serious immune-related side effects, and it is not yet known if it will work better than existing treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.